
To determine the zzso zzso zzso and the maximum tolerated doses zzso of the zzso zzso zzso combination administered biweekly in patients with advanced solid zzso 

Patients received escalated doses of zzso zzso zzso 100 zzso zzso zzso zzso 800 zzso and zzso zzso zzso 50 zzso on days 1 and 15 in cycles of every 4 zzso zzso were evaluated during the first zzso 

zzso patients zzso age 65 zzso with performance status zzso were treated on six dose escalation zzso Eleven patients zzso were chemotherapy zzso six zzso had received 1 prior chemotherapy regimen and ten zzso 2 or zzso The zzso level was reached at the doses of zzso 110 zzso zzso zzso zzso and zzso 70 zzso The zzso events were grade 4 zzso and grade 3 zzso zzso zzso was the most common adverse zzso A median of 3 cycles per patient was zzso One complete and five partial responses were observed in patients with zzso zzso zzso zzso cancer, zzso and cancer of unknown zzso No zzso drug interactions were zzso 

The recommended doses for future phase II studies of this combination are zzso 110 zzso zzso 1,000 zzso and zzso 70 zzso every 2 zzso The regimen is generally well tolerated and merits further zzso 

